---
figid: PMC7955431__JAH3-10-e019650-g001
figlink: pmc/articles/PMC7955431/figure/jah35830-fig-0001/
number: Figure 1
caption: A, The interaction of the severe acute respiratory syndrome coronavirus‐2
  (SARS‐CoV‐2) with endothelial cells (type II pneumocytes, glomerular capillary loops,
  and small intestine capillaries). Angiotensin‐converting enzyme 2 (ACE2) imbalance
  may promote susceptibility to the SARS‐CoV‐2 infection of these cell types. Furthermore,
  cell infection and induced inflammation in pericytes and endothelial cells may promote
  local apoptosis and potent inflammatory cytokines. B, Inflammatory process in the
  pulmonary alveoli, leading to pulmonary tissue edema and intravascular coagulopathy.
  C, Selection of thrombotic complications in COVID‐19 and their approximate frequency.
  D, Proposed intravascular thrombosis pathways leading to microvascular and macrovascular
  thrombosis complications. Because of the potent local and systemic cytokine production,
  the platelets are activated and interact with neutrophils. The neutrophil extracellular
  trap (NET)osis process may also stimulate thrombin production and fibrin deposition.
  The excess of fibrin deposition and fibrinolysis shutdown lead to intravascular
  thrombosis and, finally, to clinical thromboembolic complications. The pointed black
  and continued black lines denote pathway connections, pointed red lines denote inhibition,
  and green arrows denote agonism. ACE‐I indicates angiotensin‐converting enzyme inhibitor;
  anti‐Xa, anti–factor Xa; AT1, angiotensin II receptor type 1; CAHA, COVID‐19–associated
  hemostatic abnormalities; D‐D, D‐dimer; DTI, direct thrombin inhibitor; IL, interleukin;
  LMWH, low‐molecular‐weight heparin; PAI‐1, plasminogen activator inhibitor I; PFD,
  fibrin degradation product; r‐tPA, recombinant tPA; TMPRSS2, transmembrane protease
  serine 2; tPA, tissue‐type plasminogen activator; TriS, synthesized trisulfated
  heparin; and UFH, unfractionated heparin. Data derived and visual presentation modeled
  from Bikdeli et al.
pmcid: PMC7955431
papertitle: 'Coronavirus Disease 2019–Associated Thrombosis and Coagulopathy: Review
  of the Pathophysiological Characteristics and Implications for Antithrombotic Management.'
reftext: Luis Ortega‐Paz, et al. J Am Heart Assoc. 2021 Feb 2;10(3):e019650.
pmc_ranked_result_index: '119658'
pathway_score: 0.7596223
filename: JAH3-10-e019650-g001.jpg
figtitle: 'Coronavirus Disease 2019–Associated Thrombosis and Coagulopathy: Review
  of the Pathophysiological Characteristics and Implications for Antithrombotic Management'
year: '2021'
organisms:
- Homo sapiens
ndex: ''
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC7955431__JAH3-10-e019650-g001.html
  '@type': Dataset
  description: A, The interaction of the severe acute respiratory syndrome coronavirus‐2
    (SARS‐CoV‐2) with endothelial cells (type II pneumocytes, glomerular capillary
    loops, and small intestine capillaries). Angiotensin‐converting enzyme 2 (ACE2)
    imbalance may promote susceptibility to the SARS‐CoV‐2 infection of these cell
    types. Furthermore, cell infection and induced inflammation in pericytes and endothelial
    cells may promote local apoptosis and potent inflammatory cytokines. B, Inflammatory
    process in the pulmonary alveoli, leading to pulmonary tissue edema and intravascular
    coagulopathy. C, Selection of thrombotic complications in COVID‐19 and their approximate
    frequency. D, Proposed intravascular thrombosis pathways leading to microvascular
    and macrovascular thrombosis complications. Because of the potent local and systemic
    cytokine production, the platelets are activated and interact with neutrophils.
    The neutrophil extracellular trap (NET)osis process may also stimulate thrombin
    production and fibrin deposition. The excess of fibrin deposition and fibrinolysis
    shutdown lead to intravascular thrombosis and, finally, to clinical thromboembolic
    complications. The pointed black and continued black lines denote pathway connections,
    pointed red lines denote inhibition, and green arrows denote agonism. ACE‐I indicates
    angiotensin‐converting enzyme inhibitor; anti‐Xa, anti–factor Xa; AT1, angiotensin
    II receptor type 1; CAHA, COVID‐19–associated hemostatic abnormalities; D‐D, D‐dimer;
    DTI, direct thrombin inhibitor; IL, interleukin; LMWH, low‐molecular‐weight heparin;
    PAI‐1, plasminogen activator inhibitor I; PFD, fibrin degradation product; r‐tPA,
    recombinant tPA; TMPRSS2, transmembrane protease serine 2; tPA, tissue‐type plasminogen
    activator; TriS, synthesized trisulfated heparin; and UFH, unfractionated heparin.
    Data derived and visual presentation modeled from Bikdeli et al.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - TMPRSS2
  - STOM
  - ACE2
  - IL18
  - IL6
  - SERPINE1
  - SLC25A10
  - FGB
  - FGG
  - FGA
  - TRV027
  - Heparin
  - Camostat mesylate
  - Aspirin
  - Clopidogrel
  - Prasugrel
  - Dipyridamole
  - Apixaban
  - Rivaroxaban
  - UFH
  - Edoxaban
  - Betrixaban
  - Ca
  - Dabigatran
  - Argatroban
  - SARS-COV2
  - CVID-19 thrombotic
  - Pulmonary embolism
  - Myocardial injury
  - Pulmonary intravascular coagulopathy
  - thrombosis
  - Stroke
  - intravascular thrombosis
genes:
- word: TMPRSS2
  symbol: TMPRSS2
  source: hgnc_symbol
  hgnc_symbol: TMPRSS2
  entrez: '7113'
- word: stom
  symbol: STOM
  source: hgnc_symbol
  hgnc_symbol: STOM
  entrez: '2040'
- word: TMPRSS2
  symbol: TMPRSS2
  source: hgnc_symbol
  hgnc_symbol: TMPRSS2
  entrez: '7113'
- word: ACE2
  symbol: ACE2
  source: hgnc_symbol
  hgnc_symbol: ACE2
  entrez: '59272'
- word: IL18
  symbol: IL18
  source: hgnc_symbol
  hgnc_symbol: IL18
  entrez: '3606'
- word: HyperinflammationwithsystemiceffecofILI,IL-6,andIL-18
  symbol: IL-6
  source: hgnc_alias_symbol
  hgnc_symbol: IL6
  entrez: '3569'
- word: IL-6,
  symbol: IL-6
  source: hgnc_alias_symbol
  hgnc_symbol: IL6
  entrez: '3569'
- word: IL-18
  symbol: IL-18
  source: hgnc_alias_symbol
  hgnc_symbol: IL18
  entrez: '3606'
- word: PAI-1
  symbol: PAI1
  source: hgnc_prev_symbol
  hgnc_symbol: SERPINE1
  entrez: '5054'
- word: DIC
  symbol: DIC
  source: hgnc_prev_symbol
  hgnc_symbol: SLC25A10
  entrez: '1468'
- word: Fibrinogen
  symbol: Fibrinogen
  source: bioentities_symbol
  hgnc_symbol: FGB
  entrez: '2244'
- word: Fibrinogen
  symbol: Fibrinogen
  source: bioentities_symbol
  hgnc_symbol: FGG
  entrez: '2266'
- word: Fibrinogen
  symbol: Fibrinogen
  source: bioentities_symbol
  hgnc_symbol: FGA
  entrez: '2243'
chemicals:
- word: TRV027
  source: MESH
  identifier: C555534
- word: Heparin
  source: MESH
  identifier: D006493
- word: Camostat mesylate
  source: MESH
  identifier: C034532
- word: Aspirin
  source: MESH
  identifier: D001241
- word: Clopidogrel
  source: MESH
  identifier: C055162
- word: Prasugrel
  source: MESH
  identifier: C408153
- word: Dipyridamole
  source: MESH
  identifier: D004176
- word: Apixaban
  source: MESH
  identifier: C522181
- word: Rivaroxaban
  source: MESH
  identifier: C503223
- word: UFH
  source: MESH
  identifier: D006493
- word: Edoxaban
  source: MESH
  identifier: C552171
- word: Betrixaban
  source: MESH
  identifier: C543086
- word: Ca
  source: MESH
  identifier: D002118
- word: Dabigatran
  source: MESH
  identifier: C554682
- word: Argatroban
  source: MESH
  identifier: C031942
diseases:
- word: SARS-COV2
  source: MESH
  identifier: D045169
- word: CVID-19 thrombotic
  source: MESH
  identifier: D013927
- word: Pulmonary embolism
  source: MESH
  identifier: D011655
- word: Myocardial injury
  source: MESH
  identifier: D009202
- word: Pulmonary intravascular coagulopathy
  source: MESH
  identifier: D004211
- word: thrombosis
  source: MESH
  identifier: D013927
- word: Stroke
  source: MESH
  identifier: D020521
- word: intravascular thrombosis
  source: MESH
  identifier: D013927
---
